Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Psychopharmacology Bulletin|January 14, 2026
Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA BiomarkersValentin Skryabin, Anton Masyakin, Sergei Pozdniakov, et al.The Pharmacogenomics Journal|October 23, 2022
Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorderValentin Skryabin, Ilya Rozochkin, Mikhail Zastrozhin, et al.Behavioural Brain Research|March 7, 2026
Sugar Addiction at the Crossroads of Reward, Metabolism, and CultureValentin Skryabin, Moazameh Sanjari Mijan, Negar Mehryar, et al.Journal of Psychopharmacology (Oxford, England)|July 21, 2022
Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorderMikhail Zastrozhin, Valentin Skryabin, Aleksey Petukhov, et al.Drug Metabolism and Personalized Therapy|September 2, 2020
Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disordersMichael Zastrozhin, Valentin Skryabin, Alexander Sorokin, et al.Current Pharmaceutical Design|June 24, 2022
Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical PracticeGiovanni Martinotti, Stefania Chiappini, Alessio Mosca, et al.American Journal of Therapeutics|June 12, 2021
Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive DisorderMichael Zastrozhin, Valentin Skryabin, Valeriy Smirnov, et al.Current Drug Metabolism|December 29, 2022
Genetic Testing is Superior Over Endogenous Pharmacometabolomic Markers to Predict Safety of Haloperidol in Patients with Alcohol-induced Psychotic DisorderValentin Skryabin, Mikhail Zastrozhin, Alexandra Parkhomenko, et al.Pageof 2